Gilead’s remdesivir finally gets US approvalGilead’s Veklury (remdesivir) has become the first COVID-19 drug approved in the US following a nod from the Share XGilead’s remdesivir finally gets US approvalhttps://pharmaphorum.com/news/gileads-remdesivir-finally-gets-us-approval/
Gilead’s COVID-19 drug Veklury falls short in WHO’s global trialGilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in Share XGilead’s COVID-19 drug Veklury falls short in WHO’s global trialhttps://pharmaphorum.com/news/gileads-covid-19-drug-veklury-falls-short-in-whos-global-trial/
Eli Lilly and Gilead’s combination cuts COVID-19 recovery timeEli Lilly’s Olumiant (baricitinib) has a significant effect on recovery from COVID-19 when combined with Gilead Veklury (remdesivir), Share XEli Lilly and Gilead’s combination cuts COVID-19 recovery timehttps://pharmaphorum.com/news/eli-lilly-and-gileads-combination-cuts-covid-19-recovery-time/
Gilead’s rheumatoid arthritis pill approved in JapanGilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted Share XGilead’s rheumatoid arthritis pill approved in Japanhttps://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/
Gilead pays $97m to resolve US illegal kickback claimsGilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a Share XGilead pays $97m to resolve US illegal kickback claimshttps://pharmaphorum.com/news/gilead-pays-97m-to-resolve-us-illegal-kickback-claims/
Immunomedics wows ESMO with breast cancer data revealImmunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s Share XImmunomedics wows ESMO with breast cancer data revealhttps://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/
Diverse Healthcare & Pharma LIVEFree diversity & inclusion online event Share XDiverse Healthcare & Pharma LIVEhttps://pharmaphorum.com/events/diverse-healthcare-pharma-live/
Lilly’s antibody therapy cuts hospitalisation rates in COVID-19Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing Share XLilly’s antibody therapy cuts hospitalisation rates in COVID-19https://pharmaphorum.com/news/lilly-says-covid-19-antibody-therapy-cuts-hospitalisation-rates/
Gilead pays $21bn for Immunomedics ahead of breast cancer trial readoutGilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer Share XGilead pays $21bn for Immunomedics ahead of breast cancer trial readouthttps://pharmaphorum.com/news/gilead-pays-21bn-for-immunomedics-ahead-of-breast-cancer-trial-readout/
